Cabazitaxel

卡巴他赛

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameCabazitaxel
Drug Alias Name卡巴它赛cabazitaxelumDEP cabazitaxelJevtanaRPR-116258A +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation promotersTubulin depolymerization inhibitors
TargetsTubulin
Therapy Area/IndicationsBrain metastasesGastroesophageal Junction NeoplasmsSolid tumours +[24] 
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2010/06/17
Country/TerritoryCzechiaBelgiumCanada +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of LiverpoolSanofiNovartis Pharma Ag +[6] 
Inactive CompaniesWeill Medical College of Cornell UniversityJules Bordet InstituteAventis Pharma (Dagenham) +[14] 
Active IndicationsGastroesophageal Junction NeoplasmsProstatic NeoplasmsStomach Neoplasms +[5] 
Inactive IndicationsBrain metastasesSolid tumoursNeoplastic Cells, Circulating +[19] 

Other Information

ATC CodeL01CD04
Related LinksWikipediaDrugBankKEGG